Trigemina

Trigemina, Inc. develops non-opioid drug formulations and delivery systems for pain treatment. The company's products include TI-001, an intranasal oxytocin for chronic and subacute headaches, and TI-002, a non-opioid therapy addressing various types of pain, including systemic neuropathic pain. Its drugs are delivered via the nose-to-brain pathway. The company was founded in 2006 and is headquartered in Mountain View, California.